Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.
Also called NCT01520285
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 281 participants
- Sponsor
- Registry
-
NCT01520285
-
- Other papers using this trial's data
- Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01520285. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
- Acronym
- Zanidip
- Condition
- Hypertension
- Intervention (Drug)
- Zanidip
- Intervention (Drug)
- Felodipine sustained-release tablet
- Lead sponsor
- Lee's Pharmaceutical Limited
Record details
- Record id
cardio:ct-nct01520285- Content hash
f76387d1492877f842c01b38dfb25c578807fd05ce8209a3dc53ae5d9da0beb5